120800-52-4

Basic information

• Product Name: 6-MORPHOLINONICOTINIC ACID
• Synonyms: RARECHEM AL BO 2093;BUTTPARK 98\12-32;6-MORPHOLIN-4-YLNICOTINIC ACID;6-MORPHOLINONICOTINIC ACID;6-Morpholinonicotinic acid, 95+%;6-Morpholinopyridine-3-carboxylic acid;6-Morpholinonicotinic acid ,97%;6-(Morpholin-4-yl)pyridine-3-carboxylic acid, 5-Carboxy-2-(morpholin-4-yl)pyridine
• CAS NO: 120800-52-4
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21
• Product Categories: Acids and Derivatives;Heterocycles;pharmacetical
• Mol File: 120800-52-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 258-261°
• Boiling Point: 446.074 °C at 760 mmHg
• Flash Point: 223.578 °C
• Appearance: /
• Density: 1.314 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.585
• PKA: 2.70±0.10(Predicted)
• CAS DataBase Reference: 6-MORPHOLINONICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-MORPHOLINONICOTINIC ACID(120800-52-4)
• EPA Substance Registry System: 6-MORPHOLINONICOTINIC ACID(120800-52-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 120800-52-4(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C10H12N2O3/c13-10(14)8-1-2-9(11-7-8)12-3-5-15-6-4-12/h1-2,7H,3-6H2,(H,13,14)

Upstream product

• 132546-81-7 methyl 6-morpholinonicotinate 
• 313350-11-7 isopropyl 6-chloronicotinate 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 167640-97-3 isopropyl 6-morpholinonicotinate 
• 110-91-8 morpholine 

Downstream Products

• 1204535-47-6 4-{5-[(4-{[4-(Trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]-2-pyridinyl}morpholine 
• 1204535-48-7 4-[5-({(3S)-4-[(4-Chlorophenyl)sulfonyl]-3-methyl-1-piperazinyl}carbonyl)-2-pyridinyl]morpholine 
• 470463-42-4 4-(5-iodopyridin-2-yl)morpholine 
• 1418025-06-5 3-{[(6-morpholin-4-yl-pyridine-3-carbonyl)amino]methyl}-4-oxo-1-phenyl-7-trifluoromethyl-1,4-dihydro-[1,8]naphthyridine-2-carboxylic acid methyl ester 
• 1418023-64-9 7-chloro-3-{[(6-morpholin-4-yl-pyridine-3-carbonyl)amino]methyl}-4-oxo-1-phenyl-1,4-dihydro-quinoline-2-carboxylic acid dimethylamide 
• 1418025-23-6 7-fluoro-3-{[(6-morpholin-4-yl-pyridine-3-carbonyl)amino]methyl}-4-oxo-1-phenyl-1,4-dihydro-quinoline-2-carboxylic acid methyl ester 
• 132546-81-7 methyl 6-morpholinonicotinate 
• 313350-36-6 6-morpholinonicotinoyl chloride 

Relevant articles and documents

C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R1, R2, R3, R4, R5, R6, R7, 'n' and 'm' are as defined in Formula (I). The invention also relates to C-3 novel triterpenone with C-17 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES

The present application relates to novel substituted piperidinyltetrahydroquinolines, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardial vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents

Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.